Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 127 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98



前言 日中两国肺癌最新治疗的现状和展望

中岛 淳


※1 副主任医师 ※2 主任医师、教授(通讯作者)

Current status and prospects of the treatment for lung cancer in China

【Abstract】 Lung cancer is the leading cause of cancer-related mortality in global, also in China. In the past decade, much effort was made to improve the survival of lung cancer in China. In this review, we will discuss the current status and prospects of the treatment for lung cancer in China.
【Key words】 China; lung cancer; treatment; survival


张 锦

Lung Cancer Therapy in China: review and perspectives

【Abstract】 Lung cancer is a leading cause of morbidity and mortality among malignant tumors in China. More than 75 % of lung cancers are advanced stage which have little opportunity for doing surgery. Update care of lung cancer include surgery, adjuvant chemotherapy, radiotherapy, molecular targeted therapy, intervention therapy, immunotherapy and Traditional Chinese Medicine treatment. Strategy of lung cancer care is combined the comprehensivel treatmemnt with personalized therapies. The decision making should take consider the desire of patients and their family.
【Key words】 Lung cancer; Surgery; Chemotherapy; Targeted therapy; Immunotherapy



The multidisciplinary collaboration for the treatment of lung cancer in China

【Abstract】 On January 28, 2002, the Chinese first “Lung Cancer Comprehensive Treatment Center” was established in Zhongshan Hospital. On April 26, 2012, “Chinese Alliance against Lung Cancer” was launched focusing on “prevention, early diagnosis and comprehensive treatment of lung cancer.” In five years, consensus or guidelines on lung cancer treatment have been published, including early diagnosis of primary lung cancer, molecularly targeted therapy for advanced non-small cell lung cancer, diagnosis and treatment of pulmonary nodules, treatment of advanced non-small lung cancer with antiangiogenesis drugs. In order to improve the quality of treatment, Medical Internet of things(MIoT)was developed for the management of the patients in community-based hospitals.
【Key words】 Lung cancer; multidisciplinary collaboration; Internet of Things; diagnosis; treatment


矶部 威※1、仝雪霞
※1 教授

Overview of the current status of therapeutic strategies for patients with lung cancer in Japan.

【Abstract】 Lung cancer is the most frequent cause of cancer-related deaths in Japan. Recent advances of targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. We have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer.
【Key words】 non-small-cell lung cancer, driver mutation, immune checkpoint inhibitor



Multidisciplinary team for the treatment of patients with lung cancer in Japan

【Abstract】 Recent advancements in drug therapy for lung cancer require comprehensive management of various adverse events arose from various organs. It is achievable with a multidisciplinary team consisting of specifically trained cancer therapy professionals. The team responds to patients’ physical, mental, spiritual and social problems encountered during the course of cancer therapy and palliative care.
【Key words】 Lung cancer; Multidisciplinary team; Toxicity control; Cancer professional; Self-management